Trial Profile
Impact of Ticagrelor Re-load on Pharmacodynamic Profiles in Patients on Maintenance Ticagrelor Therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Ticagrelor (Primary)
- Indications Coronary artery disease; Embolism and thrombosis
- Focus Pharmacodynamics
- 17 Jun 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 16 Apr 2014 Planned End Date changed from 1 Feb 2014 to 1 Apr 2014 as reported by cliicalTrial.gov.
- 01 Jan 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.